Something strange is happening with malnutrition. It’s by far the fastest-growing cause of death in America, soaring sixfold ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access expands through telehealth — here is what the RenuviaRX platform model, ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK-1 Trial of Adults with MYBPC3-Associated HCM Expects to Repo ...

The global non-PVC IV bags market size was US$ 1.6 billion in 2021. The global non-PVC IV bags market is forecast to grow to US$ 4.1 billion by 2030 by growing at a compound annual growth rate (CAGR) ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by ...

Some people rely on these treatments when they’re in a pinch — say, when they’re feeling under the weather, battling jet lag, or fighting off illness. Others frequent IV clinics as part of their ...